Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acute decompensation of cirrhosis
Journal of Hepatology · 2026
DOI: 10.1016/j.jhep.2025.07.034 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Hepatology, 2026. Verfasst von Nipun Verma und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Postgraduate Institute of Medical Education and Research, Sector-12, Chandigarh, India. Electronic address: nipun29j@gmail.…. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Liver Cirrhosis, Acute-On-Chronic Liver Failure. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
BACKGROUND & AIMS: In patients with cirrhosis who experience acute decompensation (AD) or acute-on-chronic liver failure (ACLF), non-apoptotic forms of cell death correlate with disease severity and represent potential therapeutic targets. This study evaluated the role of cell death markers in predicting organ dysfunction, clinical course, and outcomes in AD/ACLF. METHODS: A derivation cohort of 200 individuals with AD (153 with ACLF) was recruited. Plasma cytokeratin-18 (M30: apoptosis; M65: total cell death), RIPK3 and MLKL (necroptosis), and gasdermin D (pyroptosis) were measured at baseline and day 7. A mortality prediction model was developed and validated in three independent cohorts (n = 106, 150, and 100). Liver biopsies from a fourth AD/ACLF cohort (n = 21) were stained for cell death markers. RESULTS: Cell death markers increased with disease severity, with RIPK3 levels showing the strongest association with multi-organ failure, particularly hepatic and renal (p 2.261x ULN, CLIF-C OF, and leukocytosis/leukopenia demonstrated high accuracy (AUC: 0.839) in the derivation cohort and was validated in two independent cohorts (AUC: 0.752 and 0.794, respectively). Temporal evolution was confirmed in the third validation cohort (AUC: 0.796). Hepatic RIPK1 expression was increased in individuals with ACLF and was associated with mortality in the fourth cohort. CONCLUSIONS: RIPK3-associated cell death is a key driver of organ failure and mortality in AD/ACLF. Incorporating plasma RIPK3 into prognostic models enhances risk stratification and may guide personalized use of cell death-targeted therapies in individuals with AD/ACLF. IMPACT AND IMPLICATIONS: Our study underscores the pivotal role of RIPK3 as a biomarker in acute decompensation (AD) and acute-on-chronic liver failure (ACLF), linking its elevated levels with disease progression, organ dysfunction, and mortality. In liver biopsies, hepatic RIPK1 expression was significantly higher in ACLF than AD and correlated with disease severity and mortality, supporting the hepatic origin of RIPK1 and RIPK3. Through the integration of RIPK3 into predictive models, we provide a path towards personalized therapeutic strategies for AD by targeting necroptosis. This approach has the potential to revolutionize risk stratification, enhance clinical decision-making, and improve outcomes for these high-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Postgraduate Institute of Medical Education and Research, Sector-12, Chandigarh, India. Electronic address: nipun29j@gmail.com.
- Department of Hepatology, Postgraduate Institute of Medical Education and Research, Sector-12, Chandigarh, India.
- Department of Hepatology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.
- Liver Failure Group, Institute for Liver and Digestive Health, University College London, Royal Free Campus, London, United Kingdom.
- Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum and Charité Campus Mitte, Charité - Universitaetsmedizin Berlin, Berlin, Germany.
- Liver Failure Group, Institute for Liver and Digestive Health, University College London, Royal Free Campus, London, United Kingdom. Electronic address: r.jalan@ucl.ac.uk.
Förderung
- Indian Council of Medical Research
Zitieren
APA
Verma, N., Garg, P., Kaur, P., Munjal, S., Vinod, A. P., Valsan, A., Andreola, F., Kumar, P., Saeidinejad, M., Engelmann, C., De, A., Premkumar, M., Taneja, S., Mookerjee, R. P., Duseja, A., & Jalan, R. (2026). Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acute decompensation of cirrhosis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2025.07.034
Vancouver
Verma N, Garg P, Kaur P, Munjal S, Vinod AP, Valsan A, et al. Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acute decompensation of cirrhosis. Journal of Hepatology. 2026. doi:10.1016/j.jhep.2025.07.034
BibTeX
@article{Verma2026,
author = {Verma, Nipun and Garg, Pratibha and Kaur, Parminder and Munjal, Saloni and Vinod, Ashwin P and Valsan, Arun and Andreola, Fausto and Kumar, Pavitra and Saeidinejad, MohammadMahdi and Engelmann, Cornelius and De, Arka and Premkumar, Madhumita and Taneja, Sunil and Mookerjee, Rajeshwar P and Duseja, Ajay and Jalan, Rajiv},
title = {Identification and validation of RIPK3 as a novel biomarker to predict outcomes in patients with acute decompensation of cirrhosis},
journal = {Journal of Hepatology},
year = {2026},
doi = {10.1016/j.jhep.2025.07.034}
}
EUVIMED